The erythromycin breath test predicts the clearance of midazolam.
about
Role of cytochrome P450 in drug interactionsExposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceA urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.Assessment of drug-drug interactions: concepts and approaches.Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.Characterization of the genetic variation present in CYP3A4 in three South African populations.Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.Sex-specific differences in CYP450 isoforms in humans.In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.Breath tests to phenotype drug disposition in oncology.Dealing with the complex drug-drug interactions: towards mechanistic models.Alternative Sampling Strategies for Cytochrome P450 Phenotyping.Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo.A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).Use of probe drugs as predictors of drug metabolism in humans.CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.Race but not age affects erythromycin breath test results in older hypertensive men.Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.Effect of mibefradil on CYP3A4 in vivo.Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.Variability in activity of hepatic CYP3A4 in patients infected with HIV.Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.Effect of borneol on cytochrome P450 3A enzyme and midazolam pharmacokinetics in rats.Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
P2860
Q21245066-F149FF5E-9FC5-4EA1-8CE4-55FA730EAC34Q28204828-02F96457-741B-46F7-8320-E6EC7BDF6548Q33866756-259C82FE-47B1-4FC9-89E0-1062EA78783BQ34378923-C4948294-FCE6-47AC-BB6B-70C5EC46BCB4Q36053982-8F156FEA-3F9F-4AAA-BAB6-F0A1DB1F4DAAQ36617170-F6BF3783-0DE1-49A8-AA77-2F09C366624CQ37176032-E61242D8-F7BC-4323-86E6-45C5A9AE0BF7Q37181876-AA89A737-489A-47E8-9817-A5313FE41E06Q37622756-99C73C0D-01AA-45AF-8CC8-F8332D859FB7Q38122635-156C458F-3B2D-48E1-91E8-1959ABC1F0CFQ38302225-6A74B10C-0B09-401C-BBA0-1EC0A338D83DQ38560254-25579D74-6A3F-4D87-8877-72FE7BCACE34Q39835734-8A601663-AF11-49EA-973C-29685EDBBD05Q40591949-F4A6F873-5614-45AF-9F77-9F4CF548FD42Q41361472-BCC86EB9-C7B0-4DAE-B9BD-ED49E3A3341FQ41596164-B0F8432A-B8BB-432D-AEB1-5D9D85431883Q43554159-C4CAC492-ACD3-418C-8FEC-3D6774729739Q44543753-C2006AC1-D207-4038-8289-3869397C41A2Q44601136-D09D4DD9-EFA4-4E41-8320-C12D3D0F3AEDQ44866694-96BCA3BF-A501-4713-BCD4-EA18E683EB52Q44874904-7F6DB4DE-F4FB-41CD-8253-CE97E381D7B4Q46174011-DD34F696-91B1-4E04-832E-F5FD2148342FQ46338156-4B8465B6-CCCC-4FB3-8B19-BAAD61E9FFC3Q47400761-E47D8951-1C3C-4673-A542-499650AA7E51Q47896238-B29C5EAF-95DC-46D1-BCEF-BE7F90A40C49Q48098073-E27098E2-DFE7-4940-9F5A-5C4C460886EAQ49330212-14B3A939-B7CC-4CF2-A040-EC0FC0EF7D60Q51430501-BD5834A4-C5FF-4694-AD6C-E689DE173E71Q51438639-E11B4E99-DAC9-4B30-B4C1-86E988C5D342
P2860
The erythromycin breath test predicts the clearance of midazolam.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
The erythromycin breath test predicts the clearance of midazolam.
@en
The erythromycin breath test predicts the clearance of midazolam.
@nl
type
label
The erythromycin breath test predicts the clearance of midazolam.
@en
The erythromycin breath test predicts the clearance of midazolam.
@nl
prefLabel
The erythromycin breath test predicts the clearance of midazolam.
@en
The erythromycin breath test predicts the clearance of midazolam.
@nl
P2093
P1476
The erythromycin breath test predicts the clearance of midazolam.
@en
P2093
Benedict PE
Thummel KE
Turgeon DK
Watkins PB
P2860
P356
10.1016/0009-9236(95)90261-9
P407
P577
1995-01-01T00:00:00Z